UK Launches AI Sandbox to Predict Drug Side Effects, Cut Costs
New MHRA program will test artificial intelligence systems that model medicine safety and forecast adverse reactions before clinical trials.
The UK's Medicines and Healthcare products Regulatory Agency is creating a controlled testing environment where pharmaceutical companies and researchers can develop AI systems designed to predict drug safety issues and side effects before medicines reach patients.
Lord Vallance, UK Science Minister, announced the initiative at London Tech Week. The sandbox will provide a framework for innovators to work directly with regulators while testing AI-driven approaches to understanding how medicines behave in the human body.
The scale of the problem
Adverse drug reactions currently send approximately 250,000 people to UK hospitals each year, costing the National Health Service more than £2 billion annually. Meanwhile, roughly 90% of medicines fail during development, partly because existing testing methods cannot reliably predict how drugs will perform across diverse patient populations.
The MHRA program aims to address both challenges by examining whether AI can improve predictions about drug absorption, metabolism, and potential harm. The agency plans to focus particularly on clinical data from groups historically underrepresented in trials, including children, elderly patients, and people from varied ethnic backgrounds.
How the sandbox will operate
Funding comes from the UK Government's Regulatory Innovation Office. The initial phase will accommodate up to five AI-driven approaches for testing and evaluation.
Starting in summer 2026, the MHRA will work with industry partners and academic institutions to establish operational parameters for the sandbox. The agency intends to use results from these collaborations to assess whether AI tools can reliably inform regulatory decisions about new medicine safety profiles.
Why it matters
This initiative represents a fundamental shift in how drug safety gets evaluated before human trials. If AI systems can accurately model adverse reactions across diverse populations, pharmaceutical companies could identify problems earlier in development, reducing both the financial burden of failed trials and the risk of harmful medications reaching patients. For healthcare systems, better prediction tools could prevent hundreds of thousands of hospital admissions and redirect billions in spending toward patient care rather than managing preventable drug reactions.
Broader regulatory changes
The sandbox launch coincides with other modernization efforts in UK medicine regulation. In March 2026, the MHRA and the National Institute for Health and Care Excellence began making decisions on new drugs simultaneously, streamlining the approval process.
UK Health Innovation Minister Preet Gill emphasized the government's ambition to make the NHS "the most AI-enabled healthcare system in the world" through its 10 Year Health Plan. She noted the program could reduce reliance on animal testing while accelerating the path from development to patient access.
These details were first reported by Hospital Management, a GlobalData publication.
This is an original analysis by the Omega editorial team. Source reporting: AI Watch.
Want systems like this working for your business?
Book a Call
